Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect

Bone Marrow Transplantation

Volumn 33, Issue 10, 2004, Pages 1037-1041

  Diez Martin J L ^a   Gomez Pineda A ^a   Serrano, D ^a   Carrion R ^a   Balsalobre, P ^a   Buno I ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chimaerism; Donor leukocyte infusion; FISH; Graft rejection; T cell depletion

Indexed keywords

CYCLOSPORIN A;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; BONE MARROW CELL; BONE MARROW EXAMINATION; CASE REPORT; CELL ISOLATION; CELL LINEAGE; CHIMERA; EARLY DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMAGNETIC SEPARATION; LEUKOCYTE TRANSFUSION; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; SIBLING; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIGENS, CD3; ANTIGENS, CD34; BONE MARROW; CELL TRANSPLANTATION; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKOCYTE TRANSFUSION; LEUKOCYTES; MALE; MIDDLE AGED; SIBLINGS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS; TREATMENT OUTCOME;

EID: 2942621033     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704488     Document Type: Article

References (27)

1. Armitage J. Bone marrow transplantation. New Eng J Med 1994; 330: 827-838.
2. Marmont A, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
3. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse with T-cell depletion. Ann Int Med 1988; 108: 806-814.
4. Patterson J, Prentice HG, Brenner MK et al. Graft rejection following HLA-matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 63: 221-230.
5. Chen J, Law P, Ball ED. Late graft failure. In: Ball ED, Lister J, Law P (eds.). Haematopoietic Stem Cell Therapy. Churchill Livingstone, London, 2000; pp 603-607.
6. Wolff SN. Second haematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 9: 45-52.
7. Antin JH, Childs R, Filipovich AH et al. Establishment of complete and mixed donor chimaerism after allogeneic lymphohemopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings. Biol Blood Marrow Transplant 2001; 7: 473-485.
8. Buño I, Anta B, Moreno-López E et al. Lineage-specific chimaerism quantification after T-cell depleted peripheral blood stem cell transplantation. Leuk Lymphoma 2003; 44: 659-667.
9. Dubovski J, Daxberger H, Fritsch G et al. Kinetics of chimaerism during the early post-transplant period in pediatric patients with malignant and non-malignant haematologic disorders: implications for a timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060-2069.
10. Urbano-Ispizua A, Rozman C, Pimentel P et al. The number of CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
11. Kernan NA, Bordignon C, Heller G et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989; 74: 2227-2236.
12. Papadopoulos ED, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083-1090.
13. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Eng J Med 1998; 339: 1186-1193.
14. Champlin RE, Horowitz MM, van Bekkum DW et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606-613.
15. McSweeney P, Storb R. Mixed chimaerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192-203.
16. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimaerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
17. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosupression following relapse after allogeneic bone marrow transplantation. Transplantation 1990; 50: 175-177.
18. Sykes M, Sachs D, Spitzer T. Mixed chimaerism followed by DLI for lymphohaematopoietic GVH reactions without GVHD: from animal models to patients. In: Schechter GP, Hoffman R, Schrier SL, Bajus JL (eds.) Hematology 1999. American Society of Hematology, Washington, 1999; pp 405-412.
19. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfussions in marrow grafted patients. Blood 1995; 86: 2041-2050.
20. Horwitz ME, Barrett AJ, Brown MR et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell depleted hematopoietic allograft. N Engl J Med 2001; 344: 881-888.
21. Barrett AJ, Mavroudis D, Tisdale J et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998; 21: 543-551.
22. Aker M, Kapelushnik J, Pugatsch T et al. Donor lymphocyte infusions to displace residual host haematopoietic cells after allogeneic bone marrow transplantation for B-thalassemia major. J Pediatric Hematol Oncol 1998; 20: 145-148.
23. Baron F, Dresse MF, Beguin Y. Donor lymphocyte infusion to eradicate recurrent host haematopoiesis after allogeneic BMT for sickle cell disease. Transfusion 2000; 40: 1071-1073.
24. Saarinen-Pihkala UM, Taskinen M, Vettenranta K, Hovi L. Inminent allograft rejection prevented by donor leukocyte infusions: report of two paediatric cases. Bone Marrow Transplant 2003; 31: 833-836.
25. Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E et al. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma 1999; 32: 317-325.
26. Keil F, Haas OA, Fritsch G et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor haematopoiesis predicts aplasia. Blood 1997; 89: 3113-3117.
27. Mackinnon S, Papadopoulos EB, Caralasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.